Marburg virus (MARV) and Sudan virus (SUDV) Vaccines
| Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
|---|---|
| State: | District of Columbia |
| Type of Government: | Federal |
| FSC Category: |
|
| NAICS Category: |
|
| Set Aside: | No Set aside used |
| Posted Date: | Jul 14, 2025 |
| Due Date: | Aug 26, 2025 |
| Solicitation No: | 75A50125R00006 |
| Original Source: | Please Login to View Page |
| Contact information: | Please Login to View Page |
| Bid Documents: | Please Login to View Page |
Description
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Solicitation (Updated)
- Updated Published Date: Jul 14, 2025 09:21 am EDT
- Original Published Date: Jul 13, 2025 10:24 pm EDT
- Updated Date Offers Due: Aug 26, 2025 02:00 pm EDT
- Original Date Offers Due: Aug 26, 2025 02:00 pm EDT
- Inactive Policy: 15 days after date offers due
- Updated Inactive Date: Sep 10, 2025
- Original Inactive Date: Sep 10, 2025
-
Initiative:
- None
- Original Set Aside: No Set aside used
- Product Service Code: 6505 - DRUGS AND BIOLOGICALS
-
NAICS Code:
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
-
Place of Performance:
Washington , DCUSA
The 2014 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan identifies Ebola virus and Marburg virus as high-priority threats as determined by the Department of Homeland Security to present a material threat to national security. Strategies to mitigate the threat of Ebola virus and Marburg virus include the development of vaccines suitable for protection against Ebola and Marburg virus disease respectively. BARDA is seeking vaccines that can be safely and effectively used for the U.S. civilian population in individuals with an elevated risk of exposure to Sudan virus (SUDV) and Marburg virus (MARV).
This acquisition will allow BARDA to invest Project BioShield funds for the advanced development, US Food and Drug Administration (FDA) licensure, procurement, shipping, and vendor managed inventory (VMI) storage of MARV and SUDV monovalent vaccines.
- O’NEILL HOUSE OFFICE BUILDING
- WASHINGTON , DC 20515
- USA
- Yifan Yang
- yifan.yang@hhs.gov
- Greg Smith
- greg.smith1@hhs.gov
- Jul 14, 2025 09:21 am EDTSolicitation (Updated)
- Jul 13, 2025 10:24 pm EDT Solicitation (Original)
- Jun 27, 2025 10:29 am EDT Presolicitation (Original)
Related Document
| Jun 27, 2025 | [Presolicitation (Original)] Marburg virus (MARV) and Sudan virus (SUDV) Vaccines |
| Jul 31, 2025 | [Solicitation (Updated)] Marburg virus (MARV) and Sudan virus (SUDV) Vaccines |
See Also
Basic Information Solicitation Number Doc845915 Title RFP - Interoperability and Patient Access System
District of Columbia
Due by 10/02/2026
Follow Nihon Kohden NeuroCart-Plus Active Contract Opportunity Notice ID HT001426QE040 Related Notice Department/Ind.
DEPT OF DEFENSE
Due by 9/26/2026
Basic Information Solicitation Number Doc820174 Title RFP - Interoperability and Patient Access System
District of Columbia
Due by 10/02/2026
Follow Request for Information: Internal eCommerce and Supply Inventory Solution Active Contract Opportunity
EXECUTIVE OFFICE OF THE PRESIDENT
Due by 9/24/2026